Retatrutide (LY3437943) is a cutting-edge, unimolecular triple receptor agonist. It targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, offering unprecedented potential in research involving weight management and metabolic health.
Retatrutide represents the latest frontier in incretin-based research. Unlike previous dual-agonists, Retatrutide incorporates a third mechanism by activating the glucagon receptor. This "triple-threat" approach aims to optimize energy expenditure while simultaneously regulating glucose and appetite.
By mimicking three different hormones, Retatrutide offers a synergistic effect: GIP improves insulin sensitivity, GLP-1 slows gastric emptying and suppresses appetite, and Glucagon increases metabolic rate and thermogenesis. This comprehensive profile makes it a primary subject for studies on obesity, Type 2 Diabetes, and NAFLD (Non-Alcoholic Fatty Liver Disease).
Chemical Formula: C221H342N52O68
Synonyms: LY3437943, Triple Agonist GGG
Molecular Weight: 4731.33 g/mol
CAS Number: 2381089-83-2
Appearance: Lyophilized White Powder
Purity: >99% (HPLC/MS Verified)
Solubility: Water / Bacterostatic Water
Shelf Life: 36 months (Store at -20°C)